BFC Planning’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.29K Sell
450
-69
-13% -$1.1K ﹤0.01% 2528
2026
Q2
$8.81K Sell
519
-981
-65% -$15.7K ﹤0.01% 2428
2026
Q1
$22.2K Sell
1,500
-5
-0.3% -$73 ﹤0.01% 1664
2025
Q4
$24K Buy
1,505
+1,000
+198% +$14.2K ﹤0.01% 1672
2025
Q3
$5.58K Buy
505
+500
+10,000% +$5.46K ﹤0.01% 2157
2025
Q2
$42 Hold
5
– – ﹤0.01% 2641
2025
Q1
$40 Hold
5
– – ﹤0.01% 2632
2024
Q4
$45 Hold
5
– – ﹤0.01% 2566
2024
Q3
$37 Buy
+5
New +$31 ﹤0.01% 2565

Other funds holding AUPH

BFC Planning's AUPH Position: Q3 2026 in Review

BFC Planning reduced its Aurinia Pharmaceuticals (AUPH) stake by 13% in Q3 2026, selling an estimated $1.1K and leaving 450 shares worth $7.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

BFC Planning first reported a position in AUPH in Q3 2024 and has held it in 9 quarters since. The position peaked at $24K in Q4 2025. 214 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • BFC Planning held 450 shares of Aurinia Pharmaceuticals worth $7.29K as of Q3 2026.
  • BFC Planning sold 69 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $1.1K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2528 holding.
  • BFC Planning first reported a position in Aurinia Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Aurinia Pharmaceuticals position peaked at $24K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.